GSK (GSK) said Tuesday that regulators in Europe, Japan and China have accepted separate applications to review its depemokimab drug candidate for a pair of asthma indications, including as an add-on treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps.
The company said it is also seeking approval to market the monoclonal antibody as a maintenance add-on therapy for type 2 inflammation with an eosinophilic phenotype in patients aged 12 and up whose asthma is inadequately controlled by corticosteroids.
GSK said that if approved, depemokimab will be the first ultra-long-acting biologic with six-month dosing and that it is not currently approved in any jurisdiction.
Price: 35.53, Change: +0.03, Percent Change: +0.08
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。